The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Patients with Type 2 Diabetes (TROPHIES): Patient disposition, clinical characteristics and treatment persistence at 12 months.

Guerci B, Giorgino F, Sapin H, Boye K, Lebrec J, Federici MO, Heitmann E, Dib A, Füchtenbusch M, García-Pérez LE

Diabetes, obesity & metabolism31 Aug 2022Cited by 11 (Europe PMC)

PMID35876235PMCIDPMC9804517DOI10.1111/dom.14823PepBankPUB-35876235

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanObservational studyOther
In adults with type 2 diabetes starting liraglutide in routine care, the probability of persisting with treatment at 12 months was 0.83 (95% CI 0.80 to 0.85).
In plain wordsIn adults with type 2 diabetes in routine care, most people who started liraglutide were still taking it at 12 months.
Peptide
Liraglutide
Outcome
Not applicableGLP-1 RA persistence probability at 12 months
Study
n = 991
Outcome group
Treatment adherence and retention · Whole body
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Measurements
Persistence probability
0.83 probability
liraglutide cohort
Source sentences
Summary
Both cohorts presented a high probability [95% confidence interval (CI)] of GLP-1 RA persistence [dulaglutide, 0.88 (0.86 to 0.90); liraglutide, 0.83 (0.80 to 0.85)]
1 context sentence(design, population, supporting numbers)
Summary · context
TROPHIES is a prospective, non-comparative, observational study of patients with T2D in Europe, naïve to injectable antihyperglycaemic treatments and initiating dulaglutide or liraglutide.
Report a problemFND-3587623501
02HumanObservational studyEfficacy outcome
In adults with type 2 diabetes starting liraglutide in routine care, mean HbA1c fell from baseline by 1.15 percentage points (95% CI -1.26 to -1.05) at 12 months.
In plain wordsIn adults with type 2 diabetes in routine care, HbA1c was lower after 12 months of liraglutide than at the start.
Peptide
Liraglutide
Outcome
DecreaseHbA1c change from baseline at 12 months
Study
n = 991
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Measurements
HbA1c change
−1.15%
liraglutide cohort
Source sentences
Summary
reduction in mean glycated haemoglobin percentage (95% CI) from baseline [dulaglutide, -1.18 (-1.27 to -1.08); liraglutide, -1.15 (-1.26 to -1.05)]
1 context sentence(design, population, supporting numbers)
Summary · context
TROPHIES is a prospective, non-comparative, observational study of patients with T2D in Europe, naïve to injectable antihyperglycaemic treatments and initiating dulaglutide or liraglutide.
Report a problemFND-3587623502
03HumanObservational studyEfficacy outcome
In adults with type 2 diabetes starting liraglutide in routine care, 41.2% reached the individualised HbA1c target set by the physician at baseline.
In plain wordsIn adults with type 2 diabetes in routine care, 41.2% of people on liraglutide reached the HbA1c target set by their physician.
Peptide
Liraglutide
Outcome
Not applicableProportion reaching individualised HbA1c target
Study
n = 991
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Measurements
Patients reaching HbA1c target
41.2%
liraglutide cohort
Source sentences
Summary
with 48.2% of dulaglutide and 41.2% of liraglutide patients reaching their individualized glycated haemoglobin percentage target set by the physician at baseline.
1 context sentence(design, population, supporting numbers)
Summary · context
TROPHIES is a prospective, non-comparative, observational study of patients with T2D in Europe, naïve to injectable antihyperglycaemic treatments and initiating dulaglutide or liraglutide.
Report a problemFND-3587623503
04HumanObservational studyEfficacy outcome
In adults with type 2 diabetes starting liraglutide in routine care, mean body weight fell by 3.4 kg (95% CI -3.9 to -3.0) at 12 months.
In plain wordsIn adults with type 2 diabetes in routine care, body weight was lower after 12 months of liraglutide than at the start.
Peptide
Liraglutide
Outcome
DecreaseBody weight change from baseline at 12 months
Study
n = 991
Comparator
Baseline
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Measurements
Weight change
−3.4 kg
liraglutide cohort
Source sentences
Summary
Mean weight (95% CI) change from baseline was -3.2 kg (-3.6 to -2.8) for dulaglutide and -3.4 kg (-3.9 to -3.0) for liraglutide.
1 context sentence(design, population, supporting numbers)
Summary · context
TROPHIES is a prospective, non-comparative, observational study of patients with T2D in Europe, naïve to injectable antihyperglycaemic treatments and initiating dulaglutide or liraglutide.
Report a problemFND-3587623504
05HumanObservational studyOther
In European patients with type 2 diabetes, the dulaglutide cohort had a 12-month treatment persistence probability of 0.88.
In plain wordsIn European patients with diabetes, the dulaglutide cohort had a 12-month treatment persistence probability of 0.88.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableTreatment persistence probability
Study
n: not reported in source
Outcome group
Treatment adherence and retention · Whole body
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Measurements
Persistence probability
0.88 probability
dulaglutide
95% CI
0.86 to 0.9 probability
dulaglutide persistence
Source sentences
Summary
Both cohorts presented a high probability [95% confidence interval (CI)] of GLP-1 RA persistence [dulaglutide, 0.88 (0.86 to 0.90); liraglutide, 0.83 (0.80 to 0.85)]
2 context sentences(design, population, supporting numbers)
Summary · context
TROPHIES is a prospective, non-comparative, observational study of patients with T2D in Europe, naïve to injectable antihyperglycaemic treatments and initiating dulaglutide or liraglutide.
Summary · context
By 12 months, 1014 dulaglutide and 991 liraglutide patients were eligible across France, Germany and Italy.
Report a problemFND-3587623505
06HumanObservational studyEfficacy outcome
In European patients with type 2 diabetes, dulaglutide initiation was linked to a mean glycated haemoglobin reduction of 1.18 percentage points.
In plain wordsIn European patients with diabetes, dulaglutide initiation was linked to lower glycated haemoglobin than baseline.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseGlycated haemoglobin change
Study
n: not reported in source
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Measurements
Glycated haemoglobin change
−1.18%
dulaglutide
95% CI
−1.27 to −1.08%
dulaglutide glycated haemoglobin change
Source sentences
Summary
and reduction in mean glycated haemoglobin percentage (95% CI) from baseline [dulaglutide, -1.18 (-1.27 to -1.08); liraglutide, -1.15 (-1.26 to -1.05)]
2 context sentences(design, population, supporting numbers)
Summary · context
TROPHIES is a prospective, non-comparative, observational study of patients with T2D in Europe, naïve to injectable antihyperglycaemic treatments and initiating dulaglutide or liraglutide.
Summary · context
By 12 months, 1014 dulaglutide and 991 liraglutide patients were eligible across France, Germany and Italy.
Report a problemFND-3587623506
07HumanObservational studyEfficacy outcome
In European patients with type 2 diabetes, 48.2% of dulaglutide patients reached their individualized glycated haemoglobin target.
In plain wordsIn European patients with diabetes, 48.2% of dulaglutide patients reached their individual blood sugar target.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableIndividualized glycated haemoglobin target attainment
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Measurements
Target attainment
48.2%
dulaglutide
Source sentences
Summary
with 48.2% of dulaglutide and 41.2% of liraglutide patients reaching their individualized glycated haemoglobin percentage target set by the physician at baseline.
2 context sentences(design, population, supporting numbers)
Summary · context
TROPHIES is a prospective, non-comparative, observational study of patients with T2D in Europe, naïve to injectable antihyperglycaemic treatments and initiating dulaglutide or liraglutide.
Summary · context
By 12 months, 1014 dulaglutide and 991 liraglutide patients were eligible across France, Germany and Italy.
Report a problemFND-3587623507
08HumanObservational studyEfficacy outcome
In European patients with type 2 diabetes, dulaglutide initiation was linked to a mean weight change of -3.2 kg from baseline.
In plain wordsIn European patients with diabetes, dulaglutide initiation was linked to lower weight than baseline.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseBody weight change
Study
n: not reported in source
Comparator
Baseline
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Measurements
Weight change
−3.2 kg
dulaglutide
95% CI
−3.6 to −2.8 kg
dulaglutide weight change
Source sentences
Summary
Mean weight (95% CI) change from baseline was -3.2 kg (-3.6 to -2.8) for dulaglutide and -3.4 kg (-3.9 to -3.0) for liraglutide.
2 context sentences(design, population, supporting numbers)
Summary · context
TROPHIES is a prospective, non-comparative, observational study of patients with T2D in Europe, naïve to injectable antihyperglycaemic treatments and initiating dulaglutide or liraglutide.
Summary · context
By 12 months, 1014 dulaglutide and 991 liraglutide patients were eligible across France, Germany and Italy.
Report a problemFND-3587623508

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Versions 4 to 9Current
28 Oct 2026, 02:03 UTC
The same notice was added 6 times, first on 22 Oct 2026, 02:26 UTC. The status did not change between them.
Study results updated
Version 3
21 Oct 2026, 18:59 UTC
Study data updated · source update from Europe PMC
Version 2
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.

The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Patients with Type 2 Diabetes (TROPHIES): Patient disposition, clinical characteristics and treatment persistence at 12 months.

Summary

Results from this study8

Version history

Subjects

Publication types

MeSH terms

Keywords